NuVasive (NASDAQ: NUVA) has recently received a number of price target changes and ratings updates:

  • 10/12/2017 – NuVasive had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $69.00 price target on the stock, down previously from $74.00.
  • 10/12/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $83.00 price target on the stock.
  • 10/10/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $75.00 price target on the stock.
  • 10/6/2017 – NuVasive had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $70.00 price target on the stock, down previously from $81.00.
  • 10/6/2017 – NuVasive had its “sell” rating reaffirmed by analysts at Needham & Company LLC.
  • 10/4/2017 – NuVasive had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $74.00 price target on the stock, down previously from $82.00.
  • 10/3/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $79.00 price target on the stock.
  • 9/28/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $90.00 price target on the stock.
  • 9/21/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Gabelli.
  • 9/20/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $74.00 price target on the stock, down previously from $87.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 9/18/2017 – NuVasive had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $83.00 price target on the stock.
  • 9/8/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $75.00 price target on the stock.
  • 9/7/2017 – NuVasive is now covered by analysts at BTIG Research. They set a “buy” rating and a $82.00 price target on the stock.
  • 8/28/2017 – NuVasive was downgraded by analysts at Needham & Company LLC from a “hold” rating to an “underperform” rating.
  • 8/21/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $85.00 price target on the stock.

Shares of NuVasive, Inc. (NUVA) opened at 50.58 on Thursday. The firm has a 50-day moving average of $57.81 and a 200-day moving average of $69.71. The firm has a market cap of $2.57 billion, a PE ratio of 79.65 and a beta of 1.03. NuVasive, Inc. has a 52 week low of $50.34 and a 52 week high of $81.68.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to the consensus estimate of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.40 EPS. On average, analysts expect that NuVasive, Inc. will post $1.99 EPS for the current year.

In related news, CEO Gregory T. Lucier purchased 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were bought at an average cost of $66.22 per share, with a total value of $331,100.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Peter Michael Leddy purchased 7,850 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was bought at an average cost of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. Insiders purchased a total of 14,850 shares of company stock worth $955,598 over the last three months. 1.20% of the stock is owned by insiders.

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Receive News & Ratings for NuVasive Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc and related companies with MarketBeat.com's FREE daily email newsletter.